177 related articles for article (PubMed ID: 10744046)
61. Prevalence of subclinical vitamin K deficiency in cholestatic liver disease.
Strople J; Lovell G; Heubi J
J Pediatr Gastroenterol Nutr; 2009 Jul; 49(1):78-84. PubMed ID: 19502999
[TBL] [Abstract][Full Text] [Related]
62. Effects of oral and intramuscular vitamin K prophylaxis on vitamin K1, PIVKA-II, and clotting factors in breast fed infants.
Cornelissen EA; Kollée LA; De Abreu RA; van Baal JM; Motohara K; Verbruggen B; Monnens LA
Arch Dis Child; 1992 Oct; 67(10):1250-4. PubMed ID: 1444522
[TBL] [Abstract][Full Text] [Related]
63. Assessment of KL-6 as a tumor marker in patients with hepatocellular carcinoma.
Gad A; Tanaka E; Matsumoto A; Wahab MA; Serwah Ael-H; Attia F; Ali K; Hassouba H; el-Deeb Ael-R; Ichijyo T; Umemura T; Muto H; Yoshizawa K; Kiyosawa K
World J Gastroenterol; 2005 Nov; 11(42):6607-12. PubMed ID: 16425352
[TBL] [Abstract][Full Text] [Related]
64. Des-γ-carboxyprothrombin (DCP) and NX-DCP expressions and their relationship with clinicopathological features in hepatocellular carcinoma.
Sumi A; Akiba J; Ogasawara S; Nakayama M; Nomura Y; Yasumoto M; Sanada S; Nakashima O; Abe T; Yano H
PLoS One; 2015; 10(3):e0118452. PubMed ID: 25739032
[TBL] [Abstract][Full Text] [Related]
65. Circulating levels of vitamins K1 and K2 decreased in elderly women with hip fracture.
Hodges SJ; Akesson K; Vergnaud P; Obrant K; Delmas PD
J Bone Miner Res; 1993 Oct; 8(10):1241-5. PubMed ID: 8256661
[TBL] [Abstract][Full Text] [Related]
66. Anticoagulant effects of warfarin and kinetics of K vitamins in blood and feces.
Nakamura K; Toyohira H; Kariyazono H; Ishibashi M; Saigenji H; Shimokawa S; Taira A
Artery; 1994; 21(3):148-60. PubMed ID: 7794122
[TBL] [Abstract][Full Text] [Related]
67. Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on real-world clinical data.
Yu R; Tan Z; Xiang X; Dan Y; Deng G
BMC Cancer; 2017 Sep; 17(1):608. PubMed ID: 28863782
[TBL] [Abstract][Full Text] [Related]
68. Analytical and Clinical Performance Evaluation of the Abbott Architect PIVKA Assay.
Ko DH; Hyun J; Kim HS; Park MJ; Kim JS; Park JY; Shin DH; Cho HC
Ann Clin Lab Sci; 2018 Jan; 48(1):75-80. PubMed ID: 29531000
[TBL] [Abstract][Full Text] [Related]
69. Clinical application of a new monoclonal antibody (19B7) against PIVKA-II in the diagnosis of hepatocellular carcinoma and pancreatobiliary malignancies.
Nakao A; Taniguchi K; Inoue S; Takeda S; Harada A; Nonami T; Watanabe K; Takagi H
Am J Gastroenterol; 1997 Jun; 92(6):1031-4. PubMed ID: 9177525
[TBL] [Abstract][Full Text] [Related]
70. [Effects of dibutyryl cyclic AMP for secretion of PIVKA II from huHl cells].
Ohhira M; Ono M; Kohda H; Ohta H; Sekiya C; Namiki M
Nihon Shokakibyo Gakkai Zasshi; 1991 Oct; 88(10):2728. PubMed ID: 1661791
[No Abstract] [Full Text] [Related]
71. Phylloquinone and menaquinone-4 distribution in rats: synthesis rather than uptake determines menaquinone-4 organ concentrations.
Thijssen HH; Drittij-Reijnders MJ; Fischer MA
J Nutr; 1996 Feb; 126(2):537-43. PubMed ID: 8632229
[TBL] [Abstract][Full Text] [Related]
72. Protein induced by vitamin K absence or antagonist-II versus alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: A systematic review with meta-analysis.
Xing H; Zheng YJ; Han J; Zhang H; Li ZL; Lau WY; Shen F; Yang T
Hepatobiliary Pancreat Dis Int; 2018 Dec; 17(6):487-495. PubMed ID: 30257796
[TBL] [Abstract][Full Text] [Related]
73. Clinical usefulness of double biomarkers AFP and PIVKA-II for subdividing prognostic groups in locally advanced hepatocellular carcinoma.
Park H; Kim SU; Park JY; Kim DY; Ahn SH; Chon CY; Han KH; Seong J
Liver Int; 2014 Feb; 34(2):313-21. PubMed ID: 23895043
[TBL] [Abstract][Full Text] [Related]
74. Vitamin K status in human tissues: tissue-specific accumulation of phylloquinone and menaquinone-4.
Thijssen HH; Drittij-Reijnders MJ
Br J Nutr; 1996 Jan; 75(1):121-7. PubMed ID: 8785182
[TBL] [Abstract][Full Text] [Related]
75. Des-gamma-carboxyprothrombin in patients with hepatocellular carcinoma and liver cirrhosis.
Inagaki Y; Xu HL; Hasegawa K; Aoki T; Beck Y; Sugawara Y; Tang W; Kokudo N
J Dig Dis; 2011 Dec; 12(6):481-8. PubMed ID: 22118699
[TBL] [Abstract][Full Text] [Related]
76. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study.
Kim HS; Park JW; Jang JS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Jang MK
J Clin Gastroenterol; 2009; 43(5):482-8. PubMed ID: 19197197
[TBL] [Abstract][Full Text] [Related]
77. NX-PVKA levels before and after hepatectomy of hepatocellular carcinoma as predictors of patient survival: a preliminary evaluation of an improved assay for PIVKA-II.
Nanashima A; Abo T; Taura N; Shibata H; Ichikawa T; Takagi K; Arai J; Oyama S; Nagayasu T
Anticancer Res; 2013 Jun; 33(6):2689-97. PubMed ID: 23749928
[TBL] [Abstract][Full Text] [Related]
78. Protein induced by vitamin K absence or antagonist II (PIVKA-II) producing large cell neuroendocrine carcinoma (LCNEC) of lung with multiple liver metastases: A case report.
Kurohama H; Mihara Y; Izumi Y; Kamata M; Nagashima S; Komori A; Matsuoka Y; Ueki N; Nakashima M; Ito M
Pathol Int; 2017 Feb; 67(2):105-109. PubMed ID: 28075042
[TBL] [Abstract][Full Text] [Related]
79. Surveillance of cirrhotic patients using the protein induced by vitamin K absence or antagonist II (PIVKA-II).
Nicolosi A; Pellicano R; Caviglia GP
Minerva Med; 2022 Feb; 113(1):106-108. PubMed ID: 35313441
[No Abstract] [Full Text] [Related]
80. The acquired vitamin K-dependent gamma-carboxylation deficiency in hepatocellular carcinoma involves not only prothrombin, but also protein C.
Yoshikawa Y; Sakata Y; Toda G; Oka H
Hepatology; 1988; 8(3):524-30. PubMed ID: 2836289
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
